COMMUNIQUÉS West-GlobeNewswire

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
26/08/2026
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive [...]
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
26/08/2026
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1- [...]
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
26/08/2026
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European markets KEY HIGHLIGHTS: • European Patent [...]
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
26/08/2026
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
26/08/2026
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, [...]
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
26/08/2026
- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
26/08/2026
Déclaration de transactions sur actions propres Paris, France (26 août 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 28 avril 2026, EssilorLuxottica déclare que du 17 août 2026 au 21 [...]
EssilorLuxottica: Disclosure of transactions in own shares
26/08/2026
Disclosure of transactions in own shares Paris, France (August 26, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
26/08/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 26 août 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
26/08/2026
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy In the [...]
9/11 Anniversary Nears and the Health Effects Are Still Emerging 25 Years Later
26/08/2026
World Trade Center Health Program Urges Those Exposed to 9/11 Toxins as Children or Young Adults to Learn Whether They Qualify for Specialized Care NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Twenty-five years after the [...]
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
26/08/2026
-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys [...]
Legato Emerges from Stealth with $12 Million in Funding to Pioneer a New Era of Hearing Devices with AI-Powered Hearing Glasses
26/08/2026
Poised to shake up the $15B global hearing device market with new technology that blends performance with design, Legato will debut its first product, Legato Frames, in the coming months BOSTON, Aug. 26, 2026 (GLOBE [...]
Milestone Scientific Achieves Debt-Free Balance Sheet Through Debt-to-Equity Conversion by Three Directors
26/08/2026
Conversion of $465,000 in Debt Strengthens Stockholders’ Equity and Further Aligns Directors with Shareholders ROSELAND, N.J., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (MLSS), a leading developer of [...]
Philips selected for ARPA-H program to advance AI-enabled robotic stroke care
26/08/2026
August 26, 2026 Philips receives up to US$33.7 million award from ARPA-H to expand access to AI-enabled robotic stroke care, supporting the program's goal of expanding access to specialized interventions Philips will [...]
Nucleus and Legacy Partner to Help Families Decide If IVF is Right for Them
26/08/2026
The partnership connects advanced genetic and male fertility testing, giving prospective parents more information to guide their next steps for family planning. NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Nucleus [...]
Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
26/08/2026
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Is Walking Your Dog Enough?
26/08/2026
MYOS PET Veterinary Adviser Answers Four Common Questions About Keeping Dogs Healthy and Strong CEDAR KNOLLS, N.J., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Think a daily walk is enough to keep your dog fit? Not necessarily. [...]
Oddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune Thrombocytopenia
26/08/2026
FDA grants Type B pre-IND meeting, enabling critical alignment with the Agency on the development strategy for RTX-NP Oddifact and Mabion aim to bring rituximab's well-established activity in ITP to formal FDA approval [...]

Pages